GILEAD SCIENCES, INC.

– Descovy (FTC/TAF)-based Regimens Demonstrate Comparable Efficacy and Improved Renal and Bone Laboratory Parameters Compared to Truvada...

Press Releases -- Kite’s Global CAR T-Cell Therapy Manufacturing Network Increasing Capacity by 50% to Meet Patient Demand for New Cancer...

Sharneitha Bradford spends her days helping people access cancer diagnostic care, a role she embraces as a nurse navigator. Sharneitha, and the...

Press Releases – Gilead Receives Rights to Exclusively License EVOQ’s NanoDisc Technology to Develop and Commercialize Immunotherapy Products...

Press Releases – Acquisition of XinThera Provides Gilead with Precision Small Molecules Focused on PARP1 and MK2 Inhibitors – FOSTER CITY,...

Press Releases Product Sales Excluding Veklury Increased 15% Year-Over-Year to $5.7 billion Biktarvy Sales Increased 24% Year-Over-Year to $2.7...

Gilead Statement on New NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Recommendation for Sacituzumab Govitecan-Hziy...

Press Releases – Toward Health Equity Oncology Grant ™ Supports Initiatives to Break the Cycle of Health Inequity – FOSTER CITY,...

At Gilead, we’re committed to creating a healthier world for everyone – no matter the challenges ahead of us. For more than 30 years, we’ve...

Press Releases – Daiichi Sankyo to Transfer Yescarta Marketing Authorization in Japan to Gilead Sciences K.K.– – Kite Cell Therapy Business Unit...